Disopyramide
Class Ia
IV Dose | No IV form |
Oral dose | < 2 yr.: 23-33 mg/kg/day (mean 30) 2-10 yr.: 9-24 mg/kg/day (mean 20) >10 yr.: 5-13 mg/kg/day (mean 8) divided q 6 hours, or q 12 hours for CR forms. Maximum 1200 mg/day. |
Levels | 2-5 ug/ml, poorly correlated with efficacy |
Kinetics | Peak levels at 0.5-3 hours after oral dose. (3.4-4.0 hours after controlled release form). Nonlinear kinetics due to protein binding. Elimination half-life 5-6 hours at therapeutic levels. Large Vd in children. |
Cautions | Causes significant decreases in contractility! In renal failure, active metabolite (NMD) accumulates, which is even more anticholinergic than parent compound. |
Interactions | None with digoxin. Atenolol decreases clearance and is synergistic in decreasing cardiac output. (Probably true for allbeta blockers). Phenytoin increases clearance and decreases levels. |
Preparations | Norpace capsules: 100, 150 mg Norpace CR: controlled release capsules: 100, 150 mg |
FDA approval in children | yes |